Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Karan AroraDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.
Taylor L SheehyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240, United States.ORCID 0000-0002-3100-8115
Jacob A SchulmanDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37240, United States.
Jack R LokenInterdisciplinary Materials Science Program, Vanderbilt University, Nashville, Tennessee 37240, United States.ORCID 0000-0001-7566-0001
Zachary LehmannDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37240, United States.ORCID 0009-0008-3140-045X
Blaise R KimmelDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.ORCID 0000-0002-9582-9887
Caitlin McAteeDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37240, United States.
Vijaya BhartiDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.
Payton T StoneDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.
Alissa M WeaverDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37240, United States.ORCID 0000-0002-4096-8636
Matthew TyskaDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee 37240, United States.
Rakesh Kumar PathakDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.ORCID 0000-0001-7729-6223
John T WilsonDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37212, United States.ORCID 0000-0002-9144-2634
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Chemistry-Biology Interface Training GrantT32GM065086 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, SULIKOWSKI, GARY ALLEN · 2002 to 2022
$7.0M
Molecular basis of brush border assemblyR01DK095811 · NIDDK · VANDERBILT UNIVERSITY · PI MATTHEW J TYSKA · 2013 to 2026
$4.9M
Role of I-BAR proteins in enterocyte differentiationR01DK111949 · NIDDK · VANDERBILT UNIVERSITY · PI MATTHEW J TYSKA · 2017 to 2026
$4.2M
Toward Translation of an Immunotherapeutic Nanomedicine for NeuroblastomaR01CA274675 · NCI · VANDERBILT UNIVERSITY · PI John Tanner Wilson · 2022 to 2026
$2.5M
Engineered Vaccines for Neoantigen Targeted Cancer ImmunotherapyR01CA266767 · NCI · VANDERBILT UNIVERSITY · PI John Tanner Wilson · 2022 to 2026
$2.4M
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer ImmunotherapyR01CA245134 · NCI · VANDERBILT UNIVERSITY · PI WILSON, JOHN TANNER · 2020 to 2025
$1.8M
Myosin-2 function in the enterocyte terminal webR01DK125546 · NIDDK · VANDERBILT UNIVERSITY · PI TYSKA, MATTHEW J · 2021 to 2024
A promising class of stimulator of interferon genes (STING) agonists is the non-nucleotide, small molecule, dimeric amidobenzimidazoles (diABZI), which have recently been incorporated into polymer- and antibody-drug conjugates to improve pharmacokinetics and modulate biodistribution for disease-specific applications. These approaches have leveraged diABZI variants functionalized at the 7-position of the benzimidazole for conjugation and tunable drug release from carriers. However, since this position does not interact with STING and is exposed from the binding pocket when bound in an "open lid" configuration, we sought to evaluate the activity of macromolecular diABZI conjugates that lack stimuli-responsive release and are instead conjugated to polymers via a stable amide linker. By synthesizing stable mPEG-diABZI conjugates and
Indexed as
BenzimidazolesMembrane ProteinsAnimalsHumansMacromolecular SubstancesMiceMolecular StructureSTING ProteinbenzimidazoleBenzimidazolesMacromolecular SubstancesMembrane ProteinsSTING1 protein, humanSTING Protein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Macromolecular Diamidobenzimidazole Conjugates Can Activate Stimulator of Interferon Genes. · full record | OpenQuestion